Evidence map›Paper›PMID 37880247›Full record

ArticleNature communications2023

Identification of CCZ1 as an essential lysosomal trafficking regulator in Marburg and Ebola virus infections.

Vanessa Monteil, Hyesoo Kwon, Lijo John, Cristiano Salata, Gustav Jonsson, Sabine U Vorrink, Sofia Appelberg, Sonia Youhanna, Matheus Dyczynski, Alexandra Leopoldi and 14 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Organoids in virology.Npj viruses · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 6 countries.

Vanessa MonteilKarolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-2652-5695
Hyesoo Kwon *Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-4637-4609
Lijo John *National Veterinary Institute, Uppsala, Sweden.
Cristiano Salata *Department of Molecular Medicine, University of Padova, Padova, Italy.ORCID http://orcid.org/0000-0002-5136-7406
Gustav JonssonIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.ORCID http://orcid.org/0000-0001-6692-8395
Sabine U VorrinkDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Sofia AppelbergPublic Health Agency of Sweden, Solna, Sweden.ORCID http://orcid.org/0000-0002-7381-3606
Sonia YouhannaDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Matheus DyczynskiAcus Laboratories GmbH, Cologne, Germany.
Alexandra LeopoldiIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.
Nicole LeebIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.
Jennifer VolzIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.
Astrid HagelkruysIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.ORCID http://orcid.org/0000-0003-3015-4038
Max J KellnerIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.
Stéphanie DevignotKarolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0618-5611
Georg MichlitsAcus Laboratories GmbH, Cologne, Germany.ORCID http://orcid.org/0000-0002-3337-8291
Michelle Foong-SobisIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.
Friedemann WeberInstitute for Virology, FB10-Veterinary Medicine, Justus Liebig University, Giessen, Germany.ORCID http://orcid.org/0000-0001-9737-337X
Volker M LauschkeDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1140-6204
Moritz HornAcus Laboratories GmbH, Cologne, Germany.
Heinz FeldmannLaboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.ORCID http://orcid.org/0000-0001-9448-8227
Ulrich EllingIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.ORCID http://orcid.org/0000-0002-4514-2809
Josef M PenningerIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria.ORCID http://orcid.org/0000-0002-8194-3777
Ali MirazimiKarolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden. ali.mirazimi@ki.se.ORCID http://orcid.org/0000-0003-2371-6055
Institute of Molecular Biotechnology · ATKarolinska Institutet · SEKarolinska University Hospital · SEPublic Health Agency of Sweden · SESwedish Veterinary Agency · SEJustus-Liebig-Universität Gießen · DENational Institutes of Health · USUniversity of Padua · IT

Funding

Austrian Science Fund FWF Z 271
6 · The paper itself

Abstract

Marburg and Ebola filoviruses are two of the deadliest infectious agents and several outbreaks have occurred in the last decades. Although several receptors and co-receptors have been reported for Ebola virus, key host factors remain to be elucidated. In this study, using a haploid cell screening platform, we identify the guanine nucleotide exchange factor CCZ1 as a key host factor in the early stage of filovirus replication. The critical role of CCZ1 for filovirus infections is validated in 3D primary human hepatocyte cultures and human blood-vessel organoids, both critical target sites for Ebola and Marburg virus tropism. Mechanistically, CCZ1 controls early to late endosomal trafficking of these viruses. In addition, we report that CCZ1 has a role in the endosomal trafficking of endocytosis-dependent SARS-CoV-2 infections, but not in infections by Lassa virus, which enters endo-lysosomal trafficking at the late endosome stage. Thus, we have identified an essential host pathway for filovirus infections in cell lines and engineered human target tissues. Inhibition of CCZ1 nearly completely abolishes Marburg and Ebola infections. Thus, targeting CCZ1 could potentially serve as a promising drug target for controlling infections caused by various viruses, such as SARS-CoV-2, Marburg, and Ebola.

Indexed as

EbolavirusGuanine Nucleotide Exchange FactorsHemorrhagic Fever, EbolaMarburgvirusMarburg Virus DiseaseVesicular Transport ProteinsAnimalsHumansLysosomesCCZ1 protein, humanGuanine Nucleotide Exchange FactorsVesicular Transport Proteins

Identifiers

PMID37880247
PMCPMC10600203
OpenAlexW4387950545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.